… treated for (CL) using meglumine antimoniate at a dose of 20 mg/… Meglumine antimoniate
was stopped in 13 cases. Systemic administration of pentavalent antimonials in the treatment …

… Pentavalent antimonies are the first choice treatment for ACL with a healing rate of about
75%. However, treatment response is highly dependent on the parasite species and host …

… therapeutic options. In fact, this late complication is also reported after parenteral treatment.
… parenteral and intralesional infiltration meglumine antimoniate therapies, including a phase …

… Four patients treated with systemic AM in this study and who presented poor therapeutic
response or adverse effects, were successfully treated with IL-MA in the same primary health …

… treatment presented a mean initial antimony plasma concentration of 3.39 μg/l; at the end
of treatment, … The mean antimony level in their skin at the end of the treatment was 9.24 μg/g. …

… therapy in treatment-naive patients. Combination imiquimod-meglumine antimoniate therapy
… 3 months) and a higher sustained treatment response than treatment with either meglumine …

… have been the mainstays of antileishmanial therapy for both visceral and … response to
intramuscular meglumine antimoniate (MA) alone and in combination with intralesional meglumine …

… with treatment failure in the treatment of cutaneous leishmaniasis with meglumine antimony
in a … (V.) guyanensis in Brazil: Therapeutic response to meglumine antimoniate. American …

… In this context, we aimed to evaluate the influence of treatment with meglumine antimoniate
on the specific anti-protozoan T-cell response in a case of mixed mucosal leishmaniasis and …

… remain the mainstay of systemic treatment.The mechanism of the … meglumine antimoniate
(MA) in the treatment of CL varies from 2%90% depending on dosage, duration of treatment …